Bethesda 3 Thyroid Nodule Management

This page describes interpretation and management for a thyroid nodule whose needle biopsy was read as category 3 in The Bethesda System.

Understanding Bethesda III Thyroid Nodules and How Ultrasound Appearance Guides Next Steps

When a thyroid nodule is biopsied using a fine needle, the cells are examined under a microscope and classified using the Bethesda System, which ranges from I (non-diagnostic) to VI (malignant). A Bethesda III result — called "atypia of undetermined significance" (AUS) or "follicular lesion of undetermined significance" (FLUS) — falls in a gray zone. It means the cells look mostly normal but have some features that aren't entirely typical. The overall chance of cancer in these nodules is roughly 1 in 5 (about 22%), but this varies widely depending on other factors.

Because the result is uncertain, the next step is not automatic — it depends heavily on how the nodule looks on ultrasound.

What Are the Options After a Bethesda III Result?

There are generally four paths forward:

1. Repeat the biopsy — A second needle biopsy may yield a clearer answer. If the result comes back Bethesda III again, further action is usually recommended.

2. Molecular (genetic) testing — A specialized lab test can be run on the biopsy sample to look for genetic markers associated with thyroid cancer. These tests (such as Afirma GSC or ThyroSeq v3) are quite accurate and can help determine whether the nodule is likely benign or suspicious, potentially avoiding unnecessary surgery.

3. Surveillance (watchful waiting) — Periodic ultrasound monitoring without immediate intervention, appropriate when the overall risk profile is low.

4. Surgery (diagnostic lobectomy) — Removing half of the thyroid to examine the nodule directly under a microscope. This provides a definitive answer but is the most invasive option.

How Ultrasound Appearance (TI-RADS Score) Changes the Plan

Radiologists score thyroid nodules on ultrasound using a system called ACR TI-RADS, which assigns points based on features like shape, echogenicity (brightness), margins, and the presence of calcifications. The higher the score, the more suspicious the nodule looks. Here is how the ultrasound TI-RADS level influences management of a Bethesda III nodule:

• TI-RADS 2 (not suspicious-looking): The nodule appears very benign on ultrasound, with a cancer risk below 2%. In this setting, the Bethesda III result is most likely a false alarm. Surveillance with periodic ultrasound is usually sufficient, and repeat biopsy or molecular testing may not be necessary unless other concerns exist.

• TI-RADS 3 (mildly suspicious): The cancer risk remains low (roughly 2–5%). Repeat biopsy or molecular testing is reasonable, and surveillance is still a safe option. Surgery is generally not needed unless further testing raises concern.

• TI-RADS 4 (moderately suspicious): The ultrasound shows features that raise the cancer risk to roughly 5–13%. Molecular testing is strongly recommended to help clarify the diagnosis. If molecular testing is not available, a repeat biopsy should be considered. Surgery becomes a more reasonable option, particularly if the nodule has irregular borders, tiny calcifications, or a very dark appearance on ultrasound.

• TI-RADS 5 (highly suspicious): The nodule has multiple worrisome features on ultrasound, pushing the cancer risk to 20% or higher even before considering the biopsy result. Combined with a Bethesda III result, the risk can climb substantially — some studies show it can reach 60–75% when certain types of cellular atypia are also present. In this situation, surgery or molecular testing with a low threshold for proceeding to surgery is typically recommended.

Summary:

A Bethesda III result on its own does not mean cancer — most of these nodules turn out to be benign. However, the ultrasound appearance is a powerful tool for deciding how aggressively to pursue a diagnosis. A nodule that looks reassuring on ultrasound can often be safely monitored, while one with suspicious features may warrant molecular testing or surgery. The decision is always individualized, taking into account the ultrasound findings, any available molecular test results, the patient's overall health, and their personal preferences.

References:

1.Thyroid Carcinoma.

National Comprehensive Cancer Network. Updated 2026-06-02.Guideline

2. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq V3.

The Journal of Clinical Endocrinology and Metabolism. 2023. Kim NE, Raghunathan RS, Hughes EG, et al.RCT

3. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules--2016 Update.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016. Gharib H, Papini E, Garber JR, et al.Guideline

4. Increased workload without clinical benefit: Results following implementation of the ACR‐TIRADS system for thyroid nodules.

Clinical Endocrinology. 2023. Bolland MJ, Grey A.

5. Concordance of the ACR TI-RADS Classification With Bethesda Scoring and Histopathology Risk Stratification of Thyroid Nodules.

JAMA Network Open. 2023. Huang EYF, Kao NH, Lin SY, et al.Observational

6. Malignancy Risk Stratification of Thyroid Nodules: Comparison Between the Thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association Management Guidelines.

Radiology. 2016. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY.

7. Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience.

Diagnostic Cytopathology. 2021. Köseoğlu D, Özdemir Başer Ö, Çetin Z.

8. Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/­IV thyroid nodules and inform therapeutic schedule.

Diagnostic Cytopathology. 2019. Li F, Pan D, Wu Y, et al.SR

9. Nomogram to differentiate benign and malignant thyroid nodules in the American College of Radiology Thyroid Imaging Reporting and Data System level 5.

Clinical Endocrinology. 2023. Hu T, Li Z, Peng C, et al.

10. Refining the Management of Bethesda III Thyroid Nodules by Combining Nuclear Atypia With Sonographic Suspicion.

Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2025. Li H, Lee CCY, Khoo HW, et al.Recent

11. The Clinical Value of Repeat Ultrasound-Guided Fine-Needle Aspiration Biopsy in the Management of Bethesda Category III Thyroid Nodules.

Frontiers in Endocrinology. 2025. Chen C, Fu Q, He R, et al.Recent

12. The Role of Cytological Subcategorization in Indeterminate Thyroid Nodules: Optimizing Management Strategies by Refining Malignancy Risk Stratification.

European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2026. Mouratidou S, Yanni M, Rovira A, et al.Recent